Ludmila Peres Gargano

Dr. Ludmila Peres Gargano

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 July 2020 in PharmacoEconomics
Verified
Journal Article
Closed access
PDF file
CDCarolina Zampirolli Dias
Carolina Zampirolli Dias
BGBrian Godman
Brian Godman
LGLudmila Peres Gargano
Ludmila Peres Gargano
PAPâmela Santos Azevedo
Pâmela Santos Azevedo
MGMarina Morgado Garcia
Marina Morgado Garcia
AJAugusto Afonso Guerra Junior
Augusto Afonso Guerra Junior

14 June 2021 in Expert Review of Pharmacoeconomics & Outcomes Research
Verified
Journal Article
Closed access
Isabella Piassi Dias GodóiIsabella Piassi Dias Godói
Isabella Piassi Dias Godói
TSTulio Sarmento
Tulio Sarmento
EREdna Afonso Reis
Edna Afonso Reis
LGLudmila Peres Gargano
Ludmila Peres Gargano
BGBrian Godman
Brian Godman
Cristina Mariano RuasCristina Mariano Ruas
Cristina Mariano Ruas
The new coronavirus pandemic has appreciably impacted morbidity and mortality, as well as having an economic impact worldwide. New vaccines are a potential way forward to reduce transmission rates ...

18 January 2024 in PharmacoEconomics - Open
Verified
Journal Article
Open access
PDF file
HCHenrique Lima Couto
Henrique Lima Couto
LGLudmila Peres Gargano
Ludmila Peres Gargano
VOVilmar Marques Oliveira
Vilmar Marques Oliveira
BCBertha Andrade Coelho
Bertha Andrade Coelho
EPEduardo Carvalho Pessoa
Eduardo Carvalho Pessoa
FZFernando Zanghelini
Fernando Zanghelini
Background Literature meta-analysis results show that digital breast tomosynthesis (DBT) combined with synthesized two-dimensional (s2D) mammograms can reduce recalls and improve breast cancer detection. Uncertainty regarding the screening of patients with breast cancer presents a health economic challenge, both in terms of healthcare resource use and quality of life impact on patients. Objective This study aims to estimate the cost effectiveness of DBT + s2D versus digital mammography (DM) used in a biennial breast cancer screening setting of women aged 40–69 years with scattered areas of fibroglandular breast density and heterogeneous dense breasts in the Brazilian supplementary health system. Methods A cost-effectiveness analysis was performed on the basis of clinical data obtained from a systematic review with meta-analysis performed to evaluate the analytical validity and clinical utility of DBT + s2D compared with DM. The search was conducted in the PubMed, Cochrane Library and Embase databases, with the main descriptors of the technology, a comparator, and the clinical condition in question, on 9 June 2022. The hybrid economic model (decision tree plus Markov model) simulated costs and outcomes over a lifetime for women aged 40–69 years with scattered areas of fibroglandular breast density and heterogeneous dense breasts. We analyzed incremental cost-effectiveness ratio (ICER) to measure the incremental cost difference per quality-adjusted life year (QALY) of adding DBT + s2D to breast cancer screening. Results DBT + s2D incurred a cost saving of € 954.02 per patient, in the time horizon of 30 years, compared with DM, and gained 5.1989 QALYs, which would be considered a dominant intervention. These results were confirmed in sensitivity analyses. Conclusion Switching from DM to biennial DBT + s2D was cost effective. Furthermore, reductions in false-positive recall rates should also be considered in decision making.

23 August 2025 in Hematology, Transfusion and Cell Therapy
Verified
Journal Article
Open access
LGLudmila Peres Gargano
Ludmila Peres Gargano
MFMariana Millan Fachi
Mariana Millan Fachi
LOLayssa Andrade Oliveira
Layssa Andrade Oliveira
CLClarisse Lobo
Clarisse Lobo
KMKatharina Nelly Tobos Melnikoff
Katharina Nelly Tobos Melnikoff
RLRosa Camila Lucchetta
Rosa Camila Lucchetta
Sickle cell disease is a hereditary blood disorder that significantly impacts morbidity and mortality, requiring comprehensive care. In Brazil, its management in the National Health Service follows the Brazilian Clinical Practice Guidelines, based on evidence and expert consensus. Periodic updates ensure alignment with new scientific findings. This study describes the methodology for updating the clinical guidelines for sickle cell disease and provides an overview of recommendations for diagnosis, treatment and monitoring, emphasizing the evidence and health technology assessments for prioritized technologies. The update followed the technical guide of the Brazilian Ministry of Health, and the Gradings of Recommendation, Assessment, Development and Evaluation (GRADE) approach. All the recommendations were assessed by the National Committee for Health Technology Incorporation (Conitec). The clinical guidelines panel included health technology assessment researchers, clinical experts, and policymakers. Systematic reviews assessed new evidence with stakeholder contributions being incorporated through public consultation. Cost-effectiveness analysis was applied to support new technology coverage or changes. The updated clinical guidelines provide structured recommendations for screening, diagnosis, prophylaxis, vaccination, and treatment, covering pharmacological and non-pharmacological approaches. It emphasizes patient and caregiver education to promote early recognition of complications. Expected benefits include fewer pain crises, fewer hospitalizations and transfusions, and improved fetal hemoglobin level, quality of life and survival rates. Key updates include listing epoetin alfa and 100 mg hydroxyurea tablets, expanding hydroxyurea eligibility criteria and revising monitoring protocols. The updated clinical practice guidelines standardize sickle cell disease care in the Brazilian NHS aligned with current evidence. Dissemination and integration aim to enhance healthcare delivery, while future assessments should optimize real-world implementation.

Verified
Journal Article
Open access
PDF file
LGLudmila Peres Gargano
Ludmila Peres Gargano
MBMarcus Carvalho Borin
Marcus Carvalho Borin
WPWallace Mateus Prata
Wallace Mateus Prata
JAJuliana Alvares-Teodoro
Juliana Alvares-Teodoro
FAFrancisco de Assis Acurcio
Francisco de Assis Acurcio
AJAugusto Afonso Guerra Junior
Augusto Afonso Guerra Junior
The regulation of new medicine prices must balance financial sustainability with equitable access to innovation. Value-Based Pricing (VBP) strategies seek to align drug prices with their clinical and societal impact. The Pharmaceutical Innovativeness Index (PII) is a transparent and reproducible tool proposed to assess the degree of innovativeness of new medicines, with potential to support pricing decisions within economic regulation frameworks. An exploratory qualitative study was conducted through a focus group study was conducted with experts in health economics and pharmaceutical regulation to evaluate the applicability of the PII and to discuss key domains relevant to the assessment of pharmaceutical innovation. Responses were collected anonymously using an interactive digital platform and analyzed through inductive thematic content analysis. Based on these findings, the research team developed a conceptual pricing model integrating the PII with additional value-based criteria. Two hypothetical case studies were created to explore its practical feasibility. Participants identified Added Therapeutic Value (ATV) and Unmet Therapeutic Need (UTN) as the most relevant domains, while Methodological Quality (MQ) and Study Design (SD) were also recognized as essential to ensure rigor and reduce bias. The PII scores showed strong alignment with expert judgment in the illustrative case studies. The proposed model incorporates international best practices—such as the efficiency frontier approach—and additional dimensions including safety and incremental innovation. Overall, the PII demonstrated potential to enhance transparency, consistency, and regulatory efficiency in drug pricing decisions in Brazil. However, it should currently be regarded as an exploratory framework requiring further empirical validation and regulatory adaptation before implementation.

13 June 2024 in Expert Review of Pharmacoeconomics & Outcomes Research
Verified
Journal Article
Closed access
LGLudmila Peres Gargano
Ludmila Peres Gargano
JAJuliana Alvares-Teodoro
Juliana Alvares-Teodoro
FAFrancisco de A. Acurcio
Francisco de A. Acurcio
AJAugusto Afonso Guerra Junior
Augusto Afonso Guerra Junior
BackgroundWe propose a framework to assess the value of pharmaceutical innovations, with explicit clinical and methodological parameters, based on the therapeutic value and health needs.Research design and methodsThe study was based on the adaptation of health technology assessment methods documented in the literature, which was applied to a sample of oncological drugs. Difficulties and issues during the application of those tools were identified and addressed to develop a new framework with new and revised domains and clear classification criterion for each domain. Scores were assigned to each level and domain according to their relevance to generate the final score of innovativeness.ResultsThe Pharmaceutical Innovation Index (PII) includes four domains, two related to clinical and social dimensions - Therapeutic Need and Added Therapeutic Value - and other two about methodological features - Study Design and Quality (risk of bias). The scores combined after assigned to each domain results Index of the Innovativeness of the medicines represents the degree of pharmaceutical innovation.ConclusionThis work proposes a transparent methodology with well-defined criteria and script; the algorithm developed with authors' weightings and criteria may be switched to best adjust to other applications, perspective or clinical indications, while keeping the transparency and objectiveness.